Brief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
28/10/2026 12:46
BRIEF-Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia Oct 28 (Reuters) - Sellas Life Sciences Group Inc SLS.O:
SELLAS LIFE SCIENCES REACHES 80TH EVENT IN PHASE 3 REGAL TRIAL OF GALINPEPIMUT-S (GPS) IN ACUTE MYELOID LEUKEMIA
SELLAS LIFE SCIENCES GROUP - TO REPORT TOPLINE PRIMARY ENDPOINT RESULTS FROM REGAL TRIAL THIS QUARTER
Source text: ID:nGNX7t42Vt
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses